» Articles » PMID: 39737979

Cytokine-armed Pyroptosis Induces Antitumor Immunity Against Diverse Types of Tumors

Overview
Journal Nat Commun
Specialty Biology
Date 2024 Dec 31
PMID 39737979
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammasomes are defense complexes that utilize cytokines and immunogenic cell death (ICD) to stimulate the immune system against pathogens. Inspired by their dual action, we present cytokine-armed pyroptosis as a strategy for boosting immune response against diverse types of tumors. To induce pyroptosis, we utilize designed tightly regulated gasdermin D variants comprising different pore-forming capabilities and diverse modes of activation, representing a toolbox of ICD inducers. We demonstrate that the electrogenic transfer of ICD effector-encoding plasmids into mouse melanoma tumors when combined with intratumoral expression of cytokines IL-1β, IL-12, or IL-18, enhanced anti-tumor immune responses. Careful selection of immunostimulatory molecules is, however, imperative as a combination of IL-1β and IL-18 antagonized the protective effect of pyroptosis by IFNγ-mediated upregulation of several immunosuppressive pathways. Additionally, we show that the intratumoral introduction of armed pyroptosis provides protection against distant tumors and proves effective across various tumor types without inducing systemic inflammation. Deconstructed inflammasomes thus serve as a powerful, tunable, and tumor-agnostic strategy to enhance antitumor response, even against the most resilient types of tumors.

Citing Articles

The Golden Card of Interleukin-1 Blockers in Systemic Inflammasomopathies of Childhood.

Rigante D Int J Mol Sci. 2025; 26(5).

PMID: 40076498 PMC: 11899952. DOI: 10.3390/ijms26051872.

References
1.
Rebe C, Ghiringhelli F . Interleukin-1β and Cancer. Cancers (Basel). 2020; 12(7). PMC: 7408158. DOI: 10.3390/cancers12071791. View

2.
Wang M, Bronte V, Chen P, Gritz L, Panicali D, Rosenberg S . Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol. 1995; 154(9):4685-92. PMC: 1976248. View

3.
Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay R, Luoma A . A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018; 359(6377):770-775. PMC: 5953516. DOI: 10.1126/science.aao1710. View

4.
Probst U, Fuhrmann I, Beyer L, Wiggermann P . Electrochemotherapy as a New Modality in Interventional Oncology: A Review. Technol Cancer Res Treat. 2018; 17:1533033818785329. PMC: 6048674. DOI: 10.1177/1533033818785329. View

5.
Tengesdal I, Dinarello C, Marchetti C . NLRP3 and cancer: Pathogenesis and therapeutic opportunities. Pharmacol Ther. 2023; 251:108545. PMC: 10710902. DOI: 10.1016/j.pharmthera.2023.108545. View